This is a repository copy of *Normocalcemic hyperparathyroidism: study of its prevalence and natural history*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/157483/

Version: Published Version

**Article:**
Schini, M. orcid.org/0000-0003-2204-2095, Jacques, R. orcid.org/0000-0001-6710-5403, Oakes, E. et al. (3 more authors) (2020) Normocalcemic hyperparathyroidism: study of its prevalence and natural history. The Journal of Clinical Endocrinology & Metabolism, 105 (4). dgaa084. ISSN 0021-972X

https://doi.org/10.1210/clinem/dgaa084

---

**Reuse**
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:
https://creativecommons.org/licenses/

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Normocalcemic Hyperparathyroidism: Study of its Prevalence and Natural History

Marian Schini,1 Richard M. Jacques,2 Eleanor Oakes,3 Nicola F. A. Peel,3 Jennifer S. Walsh,1 and Richard Eastell1

1Department of Oncology and Metabolism, University of Sheffield, S10 2TN, Sheffield, UK; 2School of Health and Related Research, University of Sheffield, S1 4DA, Sheffield, UK; and 3Sheffield Teaching Hospitals National Health Service Foundation Trust, S5 7AU, Sheffield, UK

ORCID numbers: 0000-0003-2204-2095 (M. Schini).

Context: Normocalcemic hyperparathyroidism (NPHPT) is characterized by persistently normal calcium levels and elevated parathyroid hormone (PTH) values, after excluding other causes of secondary hyperparathyroidism. The prevalence of the disease varies greatly and the data on the natural history of this disease are sparse and inconclusive.

Objectives: The objectives of this study are to describe the prevalence of NPHPT and its natural history in a referral population and to compare the variability of serum calcium with a group of patients with primary hyperparathyroidism (PHPT).

Design: A retrospective study was conducted over 5 years.

Setting: The setting for this study was a metabolic bone referral center.

Patients: A total of 6280 patients were referred for a bone mineral density measurement (BMD).

Main Outcome Measures: The prevalence and natural history of NPHPT and variability of calcium were the main outcome measures.

Results: We identified NPHPT patients using data from the day of the BMD measurement. We excluded patients with low estimated glomerular filtration rate (eGFR) or vitamin D, or with no measurements available. Based on the evaluation of their medical files, we identified 11 patients with NPHPT (prevalence 0.18%). Only 4 patients had consistent normocalcemia throughout their follow-up, with only 2 also having consistently high PTH. None had consistently normal eGFR or vitamin D.

Intermittent hypercalcemia was present in 7 of the 11 NPHPT patients. The mean adjusted calcium was found to be significantly lower in the NPHPT group compared with the PHPT group but higher than the control group. PTH was similar for NPHPT and PHPT. These 2 groups had similar variability in serum calcium.

Conclusions: NPHPT patients often have episodes of hypercalcemia. We believe that NPHPT is a mild form of PHPT. (J Clin Endocrinol Metab 105: 1–13, 2020)

Key Words: normocalcemic hyperparathyroidism, prevalence, natural history, epidemiology, primary hyperparathyroidism
ormocalcemic hyperparathyroidism (NPHPT) is a disorder of calcium metabolism that, despite being mentioned in the literature for several years, was officially defined only in 2009, during the Third International Workshop on Asymptomatic Primary Hyperparathyroidism (PHPT) (1). According to the latest guidelines, persistently normal calcium levels (total and ionized) and consistently elevated parathyroid hormone (PTH) values characterize NPHPT. The panel suggested that normal calcium has to be confirmed on several occasions and that an elevated PTH measurement should be confirmed on at least 2 consecutive measurements. Other causes of secondary hyperparathyroidism have to be excluded; these include medications known to affect PTH levels (diuretics, lithium, denosumab, bisphosphonates, anticonvulsants, and phosphorus), low vitamin D, chronic kidney disease (estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m²), renal calcium loss (hypercalciuria) and diseases of the gastrointestinal tract known to affect calcium absorption (celiac disease, inflammatory bowel disease, and bariatric surgery) (1-3).

NPHPT is usually encountered during the laboratory evaluation of osteoporosis and has been associated with consequences known to affect patients with PHPT (accelerated bone loss, kidney stones, higher levels of blood pressure, and higher preexisting glucose intolerance). However, there is no clear evidence for any such associations (4, 5).

The prevalence of NPHPT in the literature varies considerably, and it is reported to be between 0.1% and 8.9% (5). The reasons for this variation are that different definitions and methodologies were used in the reported studies; not all causes of secondary hyperparathyroidism were excluded, and some studies did not test the persistence of high PTH and normal calcium before evaluating the prevalence; thus the results were probably overestimated.

The data on the natural history of this disease are also sparse and inconclusive. Some studies show progression to hypercalcemia, but others do not. The way that many studies identify NPHPT patients is by testing calcium and PTH at baseline, and retesting after some time to check whether they progressed to hypercalcemia. The variability of calcium in NPHPT during the follow-up period has been poorly described. One study has described the variability as similar to the normal population, whereas patients with PHPT have been described to have more considerable variability in calcium levels (6). However, there are not enough data to draw any conclusions.

According to the proceedings of the Fourth International Workshop on Asymptomatic Primary Hyperparathyroidism, NPHPT remains incompletely described, especially regarding its epidemiology, natural history, and management (4). The criteria are not clear concerning how many measurements are needed to establish a diagnosis, which makes the matter complicated for the clinician and confusing for the patient. This study aims to identify the prevalence of NPHPT and study the natural history of this disorder in more detail. It also aimed to compare the variability of calcium and PTH between PHPT and NPHPT patients.

**Methods**

**Study population**

This work was performed at the Metabolic Bone Centre (MBC) at Sheffield Teaching Hospitals National Health Service Foundation Trust (STH NHS FT) in the United Kingdom. Data from patients referred for a bone mineral density (BMD) measurement between January 14, 2013 and July 27, 2017 were retrospectively evaluated. Patients were included in the database if they had a laboratory evaluation, including calcium and PTH, performed within 28 days of their scan. In general, this department evaluated approximately 650 patients per month at the time of the study and a laboratory workup for secondary osteoporosis was performed in patients having any of the following findings: low BMD for age (Z score < -2.0), vertebral fracture, or unexplained bone loss since the previous scan. The day of the laboratory investigations was defined to be the index day. More results of calcium and PTH before and after the index day were retrieved from hospital records and were used to study the natural history of the disease. Only data collected after January 14, 2013 were evaluated because at that point, the laboratory changed the assay for serum calcium, and this would probably affect the accuracy of the results. The end of the follow-up period was July 31, 2018.

The analysis was considered a case note review project by Sheffield Teaching Hospitals and did not require a special ethical approval (project number STH20617).

**Biochemical measurements**

Blood was drawn at any point of the day, so patients were not fasting. All the samples were analyzed in the Chemical Pathology Laboratory, STH NHS FT. Intact PTH (second generation) was measured using an immunoassay method by the Roche Cobas 8000 e602 (Roche Diagnostics GmbH). The interassay coefficient of variation (CV) measured in the laboratory is 2.2% to 3.2% at 34 ng/L, 1.6% to 1.7% at 94 ng/L, and 1.4% to 1.8% at 839 ng/L, and the reported reference interval is 15 to 65 ng/L (1.6-6.9 pmol/L).

Serum calcium was measured using a Roche/Hitachi Cobas 8000 e702 automated clinical chemistry analyzer (Roche). This method uses 5-nitro-3’-methyl-BAPTA reagent. The interassay CV as measured in the laboratory is 1.1% to 1.5% at 1.52 mmol/L and 0.6% to 1.1% at 3.07 mmol/L. Albunin measurement was performed using a Roche/Hitachi Cobas 8000 e702 analyzer (Roche). The interassay CV as measured by the laboratory is 1.5% to 2.4% at 33.9 g/L and 1.0% to 1.7% at 59.7 g/L. The albumin-adjusted calcium was used.
for this study and was calculated using the following equation based on data from the local laboratory. The method by which the laboratory established its equation was based on a protocol published by Barth et al (7).

Adjusted $Ca = Total\ Ca + [0.0172 \times (43 - Albinum)]$

The reference interval for adjusted calcium is 2.20 to 2.60 nmol/L (8.8-10.4 mg/dL).

25-hydroxyvitamin D (25(OH)D) was measured using the IDS-iSYS automated immunoassays (Immunodiagnostic Systems) until May 2013. The interassay CV reported by the manufacturer was 10.4% at 64.5 nmol/L. The assay then changed to competitive binding protein and was performed by Roche modular analytics Cobas E170 (Roche). The laboratory interassay CV for this assay is 6.5% to 9.9% at 48.2 nmol/L and 4.5% to 6.3% at 92.3 nmol/L. The Sheffield Teaching Hospitals laboratory was participating in the UK Vitamin D External Quality Assessment Scheme at the time of this study.

Creatinine was measured using a Roche/Hitachi Cobas c8000 e702 analyzer (Roche). The interassay CV for this assay was 2.7% to 6.1% at 55.7 μmol/L and 2.3% to 4.0% at 458 μmol/L. The equation used to calculate eGFR was the Modification of Diet in Renal Disease Study equation:

$$eGFR \left(\frac{mL}{min \times 1.73 m^2}\right) = 175 \times (Serum\ creatine)^{-1.154} \times age^{-0.203} \times [0.742 \ if \ female] \times [1.212 \ if \ black]$$

This equation changed in August 2015; the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation has been in use since then.

$$eGFR \left(\frac{mL}{min \times 1.73 m^2}\right) = 141 \times \min \left(\frac{Scr}{K}, 1\right)^{\alpha} \times \max \left(\frac{Scr}{K}, 1\right)^{-1.209} \times 0.993^{\beta} \times 1.018 \ if \ female \times 1.159 \ if \ black$$

Scr is serum creatinine in mg/dL, $K$ is 0.7 for female and 0.9 for male patients, $\alpha$ is -0.329 for female and -0.411 for male patients, min indicates the minimum of Scr/$K$ or 1, and max indicates the maximum of Scr/$K$ or 1 (8).

Alkaline phosphatase was measured using a Roche/Hitachi Cobas c8000 e702 analyzer. The interassay CV for this assay was 2.4% at 92.8 IU/L and 1.7% at 224 IU/L. The same analyzer was used for the measurement of serum phosphate and the interassay CV was 1.4% at 1.23 mmol/L and 1.2% at 2.04 mmol/L.

BMD was performed using dual-energy X-ray absorptiometry (DXA) of the lumbar spine and the proximal femur in posteroanterior projection. At the time of the study, there were 3 Hologic DXA scanners within the center. The least significant change (LSC) used in the MBC was 4.5% both for the spine and the hip. There were 3 scanning rooms in the department and each room has a different scanner. Room A: Hologic Discovery A has been in use since 2010. Room B: Hologic QDR4500A was in use from 2011 until September 11, 2013. The scanner was then decommissioned and replaced by a Hologic Discovery SL. Room C: Hologic Delphi C was in use until November 3, 2014. The scanner was then decommissioned and replaced by a Hologic Horizon A. The different DXA scanners were cross-calibrated at installation.

### Statistical Analysis

Because calcium and PTH are not independent variables, a bivariate statistical approach was used to define the different categories of patients. Mahalanobis distance is a multidimensional generalization of the concept of measuring the number of SDs away an observation is from the mean of a distribution. It is a classical method of defining outliers in a multivariate point cloud and is defined for each point $x_i$ by the following equation, where $MD_i$: Mahalanobis distance, $\mu$: arithmetic mean of the data set, and $S$: sample covariance matrix.

$$MD_i^2 = (x_i - \mu)^T S^{-1} (x_i - \mu)$$

The distance $MD_i$ gives the distance of point $x_i$ from the center of the cluster of points, taking into account the shape of the cluster. Observations are considered outliers if $MD^2 > X^2_{2,0.975} = 7.378$ (97.5th percentile of chi-squared distribution with 2 degrees of freedom) (9, 10). The correlation analysis of adjusted calcium and PTH was performed based on a log10 transformation of the 2 variables. A similar approach has been used in the past to evaluate the prevalence of NPHPT in a different group of patients. According to this method, participants were identified as “normal” if they were inside the ellipse and “abnormal” if they were outside (Fig. 1). To get the different categories described below, researchers used the reference interval for adjusted calcium. However, they used the geometric mean of the reference interval for PTH (11). We have adjusted this method and brought it closer to everyday clinical practice by using the clinical reference intervals both for adjusted calcium and PTH. Doing so, patients were divided into 10 categories as described below. “High” or “low” refer to values of either adjusted calcium or PTH being greater than or less than the reference interval, respectively.

To compare the variability of different analytes in the 3 groups, the overall mean and the pooled within-subject SD of each analyte was calculated. The ANOVA method was used to calculate the within-subject variance because this method addresses the case of participants having different numbers of observations. To follow this method, we first checked the assumption that the SD was unrelated to the magnitude of the measurement. This was performed graphically, by plotting the individuals’ SDs against their means and analytically by calculating a rank correlation coefficient (12).

To compare characteristics between the groups at baseline, one-way ANOVA and Kruskal-Wallis were
used to compare the quantitative data. The results are presented as mean and SD when ANOVA was used for the analysis, as geometric mean and 95% CI, when log transformation was performed before analysis with ANOVA, or as median and interquartile range if nonparametric tests were used for the analysis. The Mann-Whitney test was used to compare the 24-hour urine calcium between the NPHPT and PHPT groups. For the comparison of the overall measurements of PTH and adjusted calcium resulting from follow-up, we used a mixed linear model. Individual variability was modeled using a random effect and the difference between groups was estimated using a fixed effect.

The statistical analyses have been performed using R studio statistical software, version 1.1.442 (RStudio, Inc).

**Definitions of different groups**

As mentioned in the “Statistics” section, patients were divided into 10 categories based on their laboratory intervals for adjusted calcium and PTH. The cutoff for normal vitamin D was 50 nmol/L according to the Royal Osteoporosis Society guidelines (13). The categories were defined as follows. Normal: anyone inside the ellipse; the rest of the groups described were outside the ellipse. Hyperparathyroid hypercalcemia (HH) included patients with PHPT, and familial hypocalciuric hypercalcemia (FHH) and was defined as anyone outside the ellipse having high adjusted calcium and high PTH. Hypoparathyroidism: low adjusted calcium and low PTH. Secondary hyperparathyroidism: a) low adjusted calcium and high PTH or, b) normal adjusted calcium and high PTH with 25(OH)D less than 50 nmol/L or eGFR less than 60 mL/min/1.73 m². Non-PTH hypercalcemia: high adjusted calcium and low PTH. NPHPT: normal adjusted calcium and high PTH, given that 25(OH)D ≥ 50 nmol/L and eGFR ≥ 60 ml/min/1.73 m³. Normocalcemic hypoparathyroidism: normal adjusted calcium and low PTH. Normoparathyroid hypercalcemia: high adjusted
calcium and normal PTH. Normoparathyroid hypocalcemia: low adjusted calcium and normal PTH. Unidentified: normal adjusted calcium and normal PTH but being outside the ellipse. The groups of interest for this study were the normal population and the patients with HH and NPHPT. To characterize these groups further, the following procedures were followed.

For the NPHPT patients identified from the index date, a careful evaluation of their medical records and other laboratory investigations were performed to check for exclusion criteria according to the guidelines (see the introductory section). Renal calcium loss was defined as having 24-hour urine calcium greater than or equal to 6.25 mmol/24 h for women or 7.5 mmol/24 h for men and/or 0.1 mmol/kg/24 h or greater (14). Moreover, and to be in line with the international guidelines on persistence, only patients with persistently normal adjusted calcium and elevated PTH on 2 consecutive occasions were included.

For the HH patients, only patients with vitamin D greater than or equal to 50 nmol/L and eGFR greater than or equal to 60 mL/min/1.73m² on the index date were chosen to be used for the variability analysis. An evaluation of their medical files excluded patients with other diseases such as renal transplant. Results after parathyroid surgery were excluded. Once again, only patients with consistently high calcium and PTH on at least 2 consecutive occasions were included. To include only patients with PHPT in this group, one or more of the following criteria were used: 24-hour urine calcium greater than 2.5 mmol/24 h or fractional excretion greater than 0.02; or surgically proven PHPT (correction of high calcium after parathyroid surgery). This was performed to exclude FHH. At this point, all remaining patients in this group were defined as PHPT.

For the control population, a random sample of 300 individuals from inside the ellipse having normal eGFR and being vitamin D replete (as defined previously) on the index date was chosen.

**Results**

In total, 6293 patients attended the Metabolic Bone Centre and were assessed for secondary osteoporosis from January 2013 to July 2017. All these patients had a BMD measurement and a laboratory evaluation. Thirteen patients did not have PTH available on the index day and were excluded. The total number of patients analyzed was 6280; their mean age was 66 years (range, 16-100 years), and 4527 (72%) were female. After applying the Mahalanobis distance, the ellipse seen in Fig. 1 was drawn. In total, 5574 patients were inside the ellipse and were considered “normal,” whereas the rest were outliers and were divided into disease categories using the laboratory reference interval for calcium and PTH (Table 1).

In total, 28 patients initially fulfilled the inclusion criteria for NPHPT (normal calcium, high PTH, both on at least 2 occasions, normal eGFR and vitamin D replete on index day). A careful evaluation of their medical records and their medical history excluded 17 patients (Table 2). The natural history was then studied, using calcium measurements available from January 2013 to the end of July 2018. Two patients were excluded because of PTH inconsistency (S2406 and S3820). Eleven patients were identified as having NPHPT with persistent confirmed results of normal calcium and elevated PTH on at least 2 occasions. The prevalence was 0.18% (95% CI 0.10-0.31). The mean age of these patients was 69 years, and 91% were female. None had parathyroid surgery.

Two patterns were identified while studying the natural history: persistent normocalcemia and intermittent hypercalcemia. Intermittent hypercalcemia occurred in 7 patients (Fig. 2, lower panel). Persistent normocalcemia was rare and occurred in only 4 patients (0.06% of the whole population) (Fig. 2, upper panel). However, only 2 of these patients (S0227 and S1620) had consistently high PTH, but they were not consistently vitamin D

### Table 1. Different patient categories based on calcium metabolism disorders

| Categories                                    | No. (%)         |
|-----------------------------------------------|-----------------|
| Normal                                        | 5574 (88.76)    |
| HH                                            | 172 (2.74)      |
| Hypoparathyroid                               | 1 (0.02)        |
| Secondary hyperparathyroid                    | 291 (4.63)      |
| Non-PTH hypercalcemia                         | 6 (0.10)        |
| NPHPT                                         | 28 (0.45)       |
| NHYPO                                         | 22 (0.35)       |
| Normoparathyroid hypercalcemia                | 67 (1.07)       |
| Normoparathyroid hypocalcemia                 | 43 (0.68)       |
| Unclassified abnormal                         | 76 (1.21)       |

Normal: anyone inside the ellipse; the rest of the groups described were outside the ellipse. HH: high adjusted calcium and high PTH. Hypoparathyroidism: low adjusted calcium and low PTH. Secondary hyperparathyroidism: a) low adjusted calcium and high PTH or, b) normal adjusted calcium and high PTH with 25(OH)D < 50 nmol/L or eGFR < 60 ml/min/1.73m². Non-PTH hypercalcemia: high adjusted calcium and low PTH. NPHPT: normal adjusted calcium and high PTH, given that 25(OH)D ≥ 50 nmol/L and eGFR ≥ 60 ml/min/1.73m². NHYPO: normal adjusted calcium and low PTH. Normoparathyroid hypercalcemia: high adjusted calcium and normal PTH. Normoparathyroid hypocalcemia: low adjusted calcium and normal PTH. Unclassified abnormal: normal adjusted calcium and normal PTH but outside the ellipse.

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; eGFR, estimated glomerular filtration rate; HH, hyperparathyroid hypercalcemia; NHYPO, normocalcemic hypoparathyroidism; NPHPT, normocalcemic hyperparathyroidism; PTH, parathyroid hormone.
replete and/or did not have consistently normal eGFR (Fig. 3). If the international guidelines were strictly applied, the prevalence of NPHPT in this population would be zero.

Out of the 172 patients identified with HH, 29 were vitamin D replete and had normal eGFR on the index date. The evaluation of their medical records excluded one patient because of previous renal transplant (S2706).

Eight patients were excluded because they had one only result for PTH, and the persistence could not be confirmed, and one patient was excluded for not having at least 2 consistently high calcium measurements. One patient was excluded because FHH could not be ruled out because of lack of urine calcium (S2031). The final PHPT group had 17 patients (mean age, 69; 89% female). Twelve patients had persistent hypercalcemia (70%), whereas the remaining 6 had intermittent hypercalcemia, a pattern also seen in patients with NPHPT.

The control population group consisted of 300 individuals (mean age, 67 years; 71% female). There was no

### Table 2. Patients checked for inclusion in normocalcemic hyperparathyroidism group

| Study No. | Age, y | Sex | Medical Files Check | Persistence of Calcium and PTH | Natural History of Adjusted Calcium |
|-----------|--------|-----|---------------------|-------------------------------|----------------------------------|
| S0189     | 65     | F   | Excluded—anticonvulsants | Yes                           | Persistent normocalcemia         |
| S0227     | 59     | F   | Included             |                               |                                  |
| S0449     | 65     | F   | Excluded—treated pseudohypoparathyroidism | Yes                           | Persistent normocalcemia         |
| S0567     | 72     | F   | Excluded—tertiary hyperparathyroidism-renal transplant | Yes                           | Persistent normocalcemia         |
| S0696     | 75     | F   | Excluded—bisphosphonates | Yes                           | Intermittent hypercalcemia       |
| S0757     | 68     | F   | Included             |                               |                                  |
| S0871     | 83     | M   | Excluded—bisphosphonates | Yes                           | Persistent normocalcemia         |
| S0911     | 70     | F   | Included             |                               |                                  |
| S1194     | 74     | F   | Excluded—bisphosphonates | Yes                           | Persistent normocalcemia         |
| S1620     | 75     | F   | Included             |                               |                                  |
| S1692     | 79     | F   | Excluded—bisphosphonates | Yes                           | Intermittent hypercalcemia       |
| S1753     | 86     | M   | Included             | No                            | Intermittent hypercalcemia       |
| S2406     | 67     | F   | Included             |                               |                                  |
| S2453     | 57     | F   | Included             |                               |                                  |
| S2654     | 88     | F   | Excluded—Crohn—bisphosphonates—furosemide | Yes                           | Persistent normocalcemia         |
| S2720     | 83     | F   | Included             | Yes                           | Intermittent hypercalcemia       |
| S3021     | 64     | F   | Included             |                               |                                  |
| S3703     | 72     | F   | Excluded—anticonvulsants | Yes                           | Persistent normocalcemia         |
| S3812     | 70     | F   | Included             |                               |                                  |
| S3820     | 49     | F   | Included             |                               |                                  |
| S3841     | 84     | F   | Excluded—bisphosphonates | Yes                           | Intermittent hypercalcemia       |
| S3882     | 69     | F   | Included—hypercalciuria | No                            |                                  |
| S4392     | 66     | F   | Included             |                               |                                  |
| S4618     | 59     | F   | Included             |                               |                                  |
| S4903     | 59     | M   | Excluded—renal transplant | Yes                           | Intermittent hypercalcemia       |
| S5321     | 78     | F   | Excluded—bisphosphonates | Yes                           | Persistent normocalcemia         |
| S5369     | 64     | F   | Excluded—hypercalciuria | Yes                           | Intermittent hypercalcemia       |
| S5408     | 82     | F   | Excluded—furosemide | Yes                           | Intermittent hypercalcemia       |

Abbreviations: F, female; M, male; PTH, parathyroid hormone.

**Figure 2.** The 2 patterns identified in patients with normocalcemic hyperparathyroidism (NPHPT) when studying the natural history of adjusted calcium. Top figure, patient S1620, Persistent normocalcemia and, bottom figure, patient S2720, intermittent hypercalcemia. Arrows represent index day (day of bone mineral density scan). X-axes represent year of follow-up. Adj.Ca, adjusted calcium.
statistically significant difference in age or sex distribution between the groups (all \( P > .05 \)).

The baseline characteristics on the index date are summarized in Table 3. The 3 groups had significant differences in adjusted calcium on the index date. PTH did not differ between the NPHPT and PHPT groups. The groups had similar age- and sex-adjusted BMD results. Phosphate was significantly lower in the PHPT group compared to the control group. All the other variables studied did not have any differences between the 3 groups at baseline.

After taking all the follow-up measurements into account, the mean adjusted calcium was still found to be significantly lower in the NPHPT group compared with the PHPT group (2.52 and 2.74 mmol/L, respectively). The control group had significantly lower adjusted calcium levels than all the other groups (2.35 mmol/L, all pairwise comparisons \( P < .001 \)). PTH did not differ

---

**Figure 3.** Means and range of values of different analytes in the 11 normocalcemic hyperparathyroidism (NPHPT) patients. The dashed lines represent the reference interval for adjusted calcium, the upper reference interval for parathyroid hormone (PTH), and the desired level for 25(OH)D and estimated glomerular filtration rate (eGFR). Persistent normocalcemia was rare, only occurred in 4 patients (shown in the graph with arrows). However, only 2 patients (S0227 and S1620) had consistently high PTH. These patients were not consistently vitamin D replete and/or did not have consistently normal eGFR. PHPT, primary hyperparathyroidism.
significantly between NPHPT and PHPT (115.4 and 116.0 ng/L, respectively) but was significantly higher than in the control group (48.1 ng/L, \( P < .001 \)) (Fig. 4).

The PHPT and NPHPT groups had similar calcium variability (within-subject SD [95% CI]: 0.088 [0.079, 0.097] and 0.089 [0.080, 1.000] mmol/L, respectively). The variability of calcium in the control group was slightly lower than for PHPT and NPHPT (within-subject SD 0.083 [0.080, 0.085] mmol/L). The 24-hour urine calcium was higher in the PHPT group compared to the NPHPT groups (mean, 7.51 and 4.25 mmol/24 h, respectively) but the difference was not significant (\( P = .063 \)).

### Discussion

The international guidelines suggest that patients with NPHPT should have consistently normal values of calcium. Moreover, PTH should be high on at least 2 to 3 consecutive measurements. However, we observed in this population that persistent normocalcemia is rarely the case and using a single measurement to identify NPHPT patients can lead to overestimation of its prevalence. Patients with NPHPT usually have intermittent hypercalcemia as do PHPT patients, and we believe that NPHPT is a variant of PHPT. The intermittent nature of serum calcium both in NPHPT and PHPT results from
the relatively high variability of serum calcium in all patient groups.

The studies available for the prevalence of NPHPT use different definitions and patient populations. Often the baseline data are the only ones analyzed, without evaluation of persistence. To study the natural history, only one further measurement during follow-up is used and the variability of calcium in the follow-up period is not described.

To our knowledge, only 2 studies have reported the prevalence of NPHPT from referral centers (Table 4), one of them having the highest prevalence in the literature (8.9%) (15). The mean adjusted calcium was similar between the NPHPT group and the rest of the patients, a pattern not seen in our study. They also reported higher levels of PTH in the NPHPT group (109.5 [45.2] vs 39.1 [14.3] pg/mL, P < .001) (15). Another estimate of prevalence from a referral center is from a group in the Czech Republic. They report 187 patients (1.2%) with NPHPT (16). The prevalence of NPHPT was also studied in the general population and was reported to be between 0.1% and 6% (Table 4).

The results for the natural history remain controversial with some studies reporting no conversion to hypercalcemia (19, 24, 25), whereas others report a small percentage of patients becoming hypercalcemic (16, 18, 20, 26, 27). The problem with the studies on natural history is that, although they might check persistence at baseline on 2 to 3 occasions, they then check the laboratory measurements on only 1 occasion after a certain period; if at that point the patient has high calcium, they conclude that the patient has progressed to hypercalcemia. All the studies are summarized in Table 5. Silverberg and Bilezikian found hypercalcemia in 3 patients after 1 year of follow-up. The researchers from this paper first proposed that NPHPT is the first phase of a biphasic disease course, which can be followed by hypercalcemic hyperparathyroidism (27). The group from the Czech Republic followed the 187 patients with NPHPT for 1 to 7 years. Out of them, 151 patients (81%) remained normocalcemic, and 36 (19%) became hypercalcemic; 24 (67%) increased their calcium to high levels within 2 years, 10 (28%) within 2 to 4 years, and 2 (5%) after more than 4 years. They also reported that 23 out of the 36 patients (64%) had persistent hypercalcemia, whereas 13 (36%) had intermittent hypercalcemia, a pattern also observed in our study. The mean baseline calcium of patients who remained normocalcemic was significantly lower than the ones that became hypercalcemic (16). A more recent study evaluating NPHPT patients going through parathyroidectomy reported that 40.8% of these patients had episodes of hypercalcemia more than 1 year before surgery (28).

We believe that NPHPT is a variant of PHPT. This issue has been recently addressed by the first European Society of Endocrinology Workshop (PARAT). In its consensus statement, it mentioned that the individual variation in total calcium is 4 times narrower than the population reference interval and the interindividual variability. To ensure that a person has normal calcium, we need to know his or her individual range of variability. There is a chance that individuals might have an elevated calcium in comparison with their individual range, but still be within the normal population reference interval for calcium. These patients should probably be characterized as having PHPT and not NPHPT and be followed up and treated accordingly. This is of course after excluding causes of secondary hyperparathyroidism (30).

None of our patients progressed to persistent hypercalcemia; the patterns observed were either persistent normocalcemia or intermittent hypercalcemia. The 4 patients with persistent normocalcemia did not fulfill all the other criteria according to the international guidelines. Our hypothesis is supported by the fact that the underlying pathology of NPHPT seems to be similar to PHPT. A few studies report that multiglandular disease is more common in NPHPT (31-34) but not all reach statistical significance (35-37). However, patients included in these studies probably had secondary hyperparathyroidism resulting from vitamin D deficiency and CKD (32, 34). Most studies report that the average adenoma weight was lower in the NPHPT group compared to the PHPT group of patients (31, 35, 38).

This hypothesis, however, is not fully supported by recently published genetic data on NPHPT. Based on the hypothesis that NPHPT can be caused by PTH resistance (38), and the fact that the single-nucleotide polymorphism rs17251221 (A986S) in the calcium sensing receptor has been linked to PTH resistance, researchers in Spain recently investigated the effect of this single-nucleotide polymorphism in NPHPT patients. They recruited and prospectively studied 61 consecutive patients with NPHPT and asymptomatic PHPT. These patients had a follow-up of 1 year to check for the persistence of their laboratory investigations on at least 2 occasions. There were 38 patients (n = 24 NPHPT and n = 14 PHPT) with the wild-type genotype A986A and 23 S allele carriers (n = 20 A986S or n = 3 S986S). Seventeen NPHPT patients were S allele carriers. In these patients, the S allele was associated with significantly higher levels of serum-intact PTH (P = .024) after adjusting for factors such
Table 4. Studies evaluating prevalence of normocalcemic hyperparathyroidism

| Study                        | Population                                                                 | No. of NPHPT Patients (%) | Mean Age, y; Sex | Definition of NPHPT                                                                 | Comments/Limitations                                      |
|------------------------------|-----------------------------------------------------------------------------|---------------------------|------------------|-------------------------------------------------------------------------------------|----------------------------------------------------------|
| Marques et al (15)           | Analyzed records of 156 postmenopausal women referred to hospital to be screened for osteoporosis | 14 (8.9); 60.6; 100% female |                  | At least 2 samples of adjusted Ca and PTH. Excluded: 25(OH)D < 30 ng/mL, GFR < 40 mL/min, medications (bisphosphonates, diuretics, anticonvulsants, lithium), metabolic bone diseases, GI diseases with malabsorption, liver disease, incomplete records | Lower cutoff for eGFR                                       |
| Šiprová et al (16)           | 15 343 referrals to endocrine center. PTH measured in 1180 patients with pathological or marginal levels of total Ca, ionized Ca, serum phosphate, patients with reduced BMD, and with possible PHPT diagnosis from medical history | 187 (1.2); 61.1; 81% female at follow-up: 151 |                  | Normal total and ionized Ca and high PTH at first visit. 25(OH)D ≥ 20 ng/ml (patients with low vitamin D were treated, and PTH had to be elevated after retest at 3 mo). Excluded cases with renal insufficiency, Ca malabsorption, hypercalciuria, medications (PPI, thiazides, lithium) | Not clear if they excluded people on bisphosphonates, GFR cutoff not given |
| Berger et al (17)            | Population-based Canadian Multicentre Osteoporosis Study: prospective cohort of 9423 community-dwelling women and men living within 50 km of 9 Canadian cites. 566 men and 1306 women (n = 1875) age ≥ 35 y with available PTH | 62 (3.31); NA; NA |                  | Normal total Ca and high PTH, 25(OH)D ≥ 50 nmol/L, eGFR ≥ 60 mL/min/1.73 m² | 85% users of antiresorptives and diuretics. Not clear if they checked persistence or other causes of secondary hyperparathyroidism |
| Cusano et al (18)            | DHS: population-based cohort study. Evaluated 3450 individuals age 18 to 65 y with Ca and PTH values. 2122 patients had follow-up data 8 y later | 108 (3.1); 41.3; 38% female at follow-up: 13 (0.6%) |                  | Normal albumin-adjusted Ca and high PTH. Excluded renal insufficiency (GFR < 60 mL/min), 25(OH)D < 20 ng/ml, thiazide, or lithium use | Only single laboratory values and did not check persistence. Lack of data regarding medical history and parathyroid surgery. Not clear if they excluded patients on bisphosphonates or with hypercalciuria |
| Cusano et al (18)            | Osteoporotic Fractures in Men, an unselected community-based study in age ≥ 65 y. Evaluated 2364 men with calcium and PTH values | 9 (0.4); 70.0; 0% female |                  | Normal albumin-adjusted Ca and high PTH. Excluded renal insufficiency (GFR < 60 mL/min), 25(OH)D < 20 ng/ml, thiazide use | Same as DHS |
| García-Martín et al (19)     | Prospective study of 100 healthy postmenopausal women. All had follow-up 6 y later | 6 (6); 56.3; 100% female at follow-up: 6 |                  | Normal adjusted Ca and high PTH. 25(OH)D ≥ 30 ng/mL, normal renal function (creatinine clearance > 70 mL/min/1.73 m²) | Not clear if they excluded patients on medications. Not clear what they defined as “healthy.” |
| Kontogeorgos et al (20)      | Random population sample of 2400 men and women age 25 to 64 years from World Health Organization MONItoring of trends and determinants for Cardiovascular disease project. Investigation in 1995, data on 608, including all women age 45 to 64 y, every fourth woman age 25 to 44 y, and every fourth man in all age groups (25-64 y), n = 410 | 12 (2.0%); 53.3; NA; at follow-up: 1 (0.2%) |                  | Normal total Ca and high PTH, 25(OH) ≥ 50 nmol/L, normal renal function | Patients on bisphosphonates and diuretics. Only one blood measurement at baseline |
| Study                                      | Population                                                                 | No. of NPHPT Patients (%) | Mean Age, y; Sex | Definition of NPHPT                                                                 | Comments/Limitations                                                                 |
|-------------------------------------------|------------------------------------------------------------------------------|---------------------------|------------------|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| Lundgren et al  Sweden (community) (21)   | Population-based mammography screening in 5202 women age 55 to 75 years     | 28 (0.5); no data on age; 100% female |                  | Normal ionized Ca. Creatinine < 160 µmol/L and either a) serum Ca < 2.50 mmol/L + PTH > 55 ng/L or b) serum Ca 2.50 to 2.60 mmol/L + PTH ≥ 35 ng/L. Checked for persistence (≥ 3 occasions). Excluded malabsorption and family history of hypercalcemia | Did not exclude patients on medications known to cause secondary hyperparathyroidism. No vitamin D check |
| Palermo et al  Five European cities in UK, France, Germany (community) (11) | Recruited 2419 women (age 55-79 y) and 258 women (age 30-40 y) for Osteoporosis and Ultrasound Study. Follow-up after 6 y in 1416 patients | 1 (0.1); no information on age; 100% female; at follow-up: none |                  | Mahalanobis distance used: NPHPT anyone outside ellipse with normal adjusted Ca, high PTH, 25(OH) D ≥ 50 nmol/L, GFR ≥ 60 mL/min | Unclear if they excluded patients with other causes of secondary hyperparathyroidism (diseases, medication) |
| Rosário et al Brazil (community) (22)     | Prospectively recruited adults ≥ 18 y to undergo thyroidectomy for nodular disease. Excluded patients who had ultrasound because of PHPT, patients with a history of nephrolithiasis, nephrocalcinosis, and pathological fracture, personal or family history of multiple endocrine neoplasia, and diagnosis of medullary thyroid cancer. N = 676 | 46 (6.8%). Only 8.7% had altered parathyroid glands (adenoma) during gland exploration (0.6% of cohort) | Criterion 1: 46 (6.8%). Only 8.7% had altered parathyroid glands (adenoma) during gland exploration (0.6% of cohort) | Criterion 1: Normal adjusted and ionized Ca and high PTH, confirmed at 2 measurements, 25(OH)D ≥ 20 ng/dL, eGFR ≥ 40 mL/min/1.73 m². Excluded: those on diuretics, lithium, bisphosphonates, denosumab, recombinant PTH, corticosteroids; patients with primary aldosteronism, suspicion or known diagnosis of malabsorption, hyperparaphosphatemia, Ca/urinary creatine ratio ≥ 0.25, or thyroid dysfunction. Screened for celiac disease and excluded patients with positive antibodies | Criterion 2: same as criterion 1 but 25(OH) D ≥ 20 ng/dL, eGFR ≥ 60 mL/min/1.73 m² |
| Vignali et al Italy (community) (23)       | Residents of village in Southern Italy in 2010 (685 with full data)         | 3 (0.4); 47; 0% female   |                  | Normal adjusted Ca and high PTH, 25(OH) D ≥ 30 ng/mL, eGFR ≥ 60 mL/min/1.73 m². Excluded people on bisphosphonates and thiazides, overt GI and metabolic bone diseases | Did not check persistence and could not check urine Ca |

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; BMD, bone mineral density; Ca, calcium; DHS, Dallas Heart Study; eGFR, estimated glomerular filtration rate; GI, gastrointestinal; NA, not available; NPHPT, normocalcemic hyperparathyroidism; PHPT, primary hyperparathyroidism; PPI, proton pump inhibitor; PTH, parathyroid hormone.
## Table 5. Studies evaluating natural history of normocalcemic hyperparathyroidism

| Study | Study Population; Duration of Follow-up | Definition of NPHPT | Progression to Hypercalcemia |
|-------|----------------------------------------|---------------------|-----------------------------|
| Ayturk et al (24) | 20; 18 mo (6-mo intervals) | Normal Ca and high PTH confirmed in at least 3 measurements. Excluded chronic renal or liver failure, vitamin D deficiency, secondary hyperparathyroidism, treatment with lithium. No treatments with thiazide and loop diuretics, phenytoin, lithium, glucocorticoids, or oral contraceptives during study | None progressed to hypercalcemia |
| Tordjman et al (25) | 20; 4.1 ± 3.2 y | Normal total Ca and high PTH secondary hyperparathyroidism excluded (impaired renal function). Three patients had low vitamin D levels but correction did not alter PTH levels and did not unmask hypercalcemia. Six patients had > 300 mg/24 h urine Ca and were given thiazides without affecting PTH levels. Persistence not checked at baseline | None of the patients developed hypercalcemia. Mean serum calcium levels did not change significantly (baseline vs last) |
| Garcia-Martin et al (19) | 6; 1 y | Normal adjusted Ca and high PTH. 25(OH)D > 30 ng/mL, normal renal function (creatinine clearance > 70 mL/min/1.73 m²). Persistence not checked at baseline | All patients remained normocalcemic |
| Cusano et al (18) | 64; 8 y | Normal albumin-adjusted Ca and high PTH. Excluded renal insufficiency (GFR < 60 mL/min), 25(OH)D ≤ 20 ng/mL, thiazide or lithium use. Persistence not checked at baseline | Hypercalcemia: 1 (1.6%). Persistent normal Ca, high PTH: 13 (20%) |
| Diri et al (26) | 16; 4 y | Normal total Ca and high PTH, 25(OH)D > 20 ng/mL, repeated Ca and PTH measurements 3× with 2-wk intervals, no history of renal or liver diseases, no prescriptions known to affect Ca level | One (6.25%) developed hypercalcemia |
| Kontogeorgos et al (20) | 12; 13 y. First assessment 1995, second 2008 to 2009, participation rate 67% | Normal total Ca and high PTH, 25(OH) ≥ 50 nmol/L, normal renal function | One (8.33%) developed hypercalcemia. Persistent normal Ca, high PTH: 1 (8.33%). Two had vitamin D deficiency, normal Ca, and high PTH |
| Silverberg et al (27) | 22; up to 1 y | Normal adjusted calcium and high PTH. Confirmed on at least 2 occasions, 8 patients had normal ionized Ca, 25(OH) D > 20 ng/mL. Excluded FHH, liver disease, renal disease, urinary calcium > 87.5mmol/24h, G1 disease with malabsorption, metabolic bone disease, medications (lithium, thiazide, oestrogens, loop diuretics, bisphosphonates, anticonvulsants) | Three (14%) developed hypercalcemia |
| Siprova et al (16) | 187; 1 to 7 y | Normal total and ionized Ca and high PTH. 25(OH)D ≥ 20 ng/ml (patients with low vitamin D were treated, and PTH had to be elevated after retested at 3 mo). Excluded cases with renal insufficiency, calcium malabsorption, hypercalcuria, medications (PPI, thiazides, lithium) | 151 (81%) remained normocalcemic for whole follow-up period. 36 (19%) became hypercalcemic |
| Lowe et al (29) | 37; 3.1 ± 0.3 y | Normal adjusted Ca and high PTH, 25(OH)D ≥ 50 nmol/L. Excluded cases with renal insufficiency (GFR < 40 mL/min/1.73 m²), liver disease; significant hypercalcuria > 350 mg/24 h, thiazide diuretic or lithium use, other metabolic bone diseases (eg, Paget disease) | Seven (19%) became hypercalcemic. Patients who became hypercalcemic had higher Ca levels, higher urinary calcium excretion, and were older |

**Abbreviations:** 25(OH)D, 25-hydroxyvitamin D; Ca, calcium; eGFR, estimated glomerular filtration rate; FHH, familial hypocalciuric hypercalcemia; NA, not available; NPHPT, normocalcemic hyperparathyroidism; PHPT: primary hyperparathyroidism; PPI, proton pump inhibitor; PTH, parathyroid hormone.
as vitamin D and calcium concentrations. There was no association with the S allele in PHPT patients (39).

In our series, we found a similar variability of adjusted calcium in patients with NPHPT and PHPT. The variability of calcium and PTH has been studied previously in a prospective series of surgically proven PHPT. In this study (6), the definition of NPHPT was every measurement of calcium being less than 10.2 mg/dL (2.55 mmol/L), and only 1.1% of the patients fulfilled this criterion. Almost all the patients with PHPT had variable calcium levels, with 74% having intermittent hypercalcemia within the previous year. This study did not include a control group but mentioned that serum calcium was more variable in PHPT patients compared to the same patients before developing this disorder. The variability before was described to be 0.19 (0.09) mg/dL (0.0475 [0.0225] mmol/L). After conversion to PHPT, the variability more than doubled (0.1 [0.0825] mmol/L), with calcium varying by more than 1 mg/dL (0.25 mmol/L) from month to month in some cases. The authors suggested this could be a loss of calcium homeostasis by a parathyroid tumor. Patients with NPHPT were reported as an exception, presenting with minimal variability, like the one in the patients before PHPT. Minimal variability is not the finding from our study, because NPHPT and PHPT patients both had similar calcium variability (6).

The variability described in calcium in these patients complicates their monitoring. According to the international guidelines, calcium and PTH should be tested every year, whereas a BMD check should be performed every 1 to 2 years. If there is a progression to hypercalcemia, patients should be treated according to the guidelines on asymptomatic PHPT (40). However, a majority of these patients have intermittent hypercalcemia; the subsequent results might be confusing both for the care provider and the patient as to whether surgery would be recommended.

We used a statistical approach to define the different categories in this population. Our results showed that a large percentage of participants were considered “normal” (inside the ellipse) using this approach, even though they had elevated PTH according to the reference interval. The individuals who were normal but had higher PTH than the reference interval were found to be significantly older than those who were normal and also had normal PTH according to the current reference interval (data not shown). These results align well with the fact that PTH is known to increase with age. This increase was recently found to be independent of 25(OH)D, ionized calcium, phosphate, and renal function (41). It has been previously suggested that age-related PTH reference intervals should be established (2). Our study supports this statement. By using the current reference interval in everyday practice, we are probably overdiagnosing NPHPT and may be subjecting older individuals to unnecessary testing. An increase of the upper limit of the reference interval in PTH could alter the number of patients diagnosed with this disorder.

This study describes the largest population ever studied to identify NPHPT and provides data during a long follow-up period (5 years). There are several limitations to this study, however. The samples were not fasting, blood was taken with a tourniquet, and ionized calcium was not available. The methods for vitamin D and eGFR changed during the follow-up period and that might have affected some results. We have used a 25(OH)D threshold of 50 nmol/L for identifying high PTH due to D deficiency, but the cross-sectional data indicate that values between 50 and 75 nmol/L might be associated with slight elevations of PTH, thus resulting in overdiagnosis of NPHPT. Many researchers recommend using a higher cutoff of 75 nmol/L. We have used the cutoff advised by the Royal Osteoporosis Society guidelines and the Fourth International Workshop on Asymptomatic Primary Hyperparathyroidism (2, 13). The impact of implementing the CKD-EPI equation is that it may have improved the accuracy in patients with an eGFR of 50 to 60 mL/min/1.73 m² and might have resulted in fewer people being clustered as CKD. However, it might have increased the number of older people having CKD. The equation used to calculate the pooled SD cannot really distinguish between variations due to the progression of the disease or those due to natural variation. We assume that when taking measurements close to each other, the pooled SD would estimate the method variation and the variability of the assay. Because the measurements in this population are further away, we believe that the variability is due to the within-subject variability. Moreover, none of our patients had progressive disease as seen in the natural history graphs, so we believe that this is all due to natural variation. This was a retrospective observational study and the number of measurements varied from patient to patient. The interval between the measurements was not the same, as expected in a real-life setting. This limited the possibility of further analyses. The analysis for the within-subject SD did not take into account the effect of time. Ideally, to give a more accurate estimate of the variance, a prospective observational study should be designed having the same number of measurements for each patient at regular intervals. The analysis should preferably be conducted using a model that takes time into account. Despite the limitations, this study provided
a guide to how adjusted calcium varies between the different groups described.

The patients studied were identified from a referral center and were evaluated for causes of secondary osteoporosis so they might be different from the general population. On the other hand, NPHPT is usually diagnosed during the evaluation of secondary osteoporosis and thus, mainly found in referral centers. Studying a referral population has the advantage of evaluating how common NPHPT is in a referral population with osteoporosis and whether screening for NPHPT is useful.

Another group that is mentioned in this cohort, is the normoparathyroid hypercalcemia one. These patients were previously been described to progress to PHPT (42). It was not within the scope of this study to evaluate these patients further, but it is among our future plans.

The question resulting from this study is whether NPHPT exists and, if it does, whether the current definition used is the most appropriate. We believe there are 3 ways forward. If we adjust the reference interval for PTH for age and use the current definition, NPHPT may not exist, as shown in this study. Another approach would be to revisit the current definition, and NPHPT should be defined as having the average calcium within normal limits (and not requiring it to be persistently normal). Using the same approach, PHPT should be considered as having a high average calcium. In this case, 10 out of our 11 included patients would be classified as NPHPT, and 16 out of 17 PHPT patients would be classified as having PHPT (Fig. 5).

Another way forward would be to consider NPHPT as a variant of PHPT and follow-up and treat according to the current guidelines as suggested in the consensus statement of the first PARAT. This is supported by many studies in the literature showing similar characteristics from these 2 groups of patients. It is also supported by the fact that the underlying pathology of NPHPT seems to be similar to PHPT. We believe, based on the results from this study, that this is the best approach to follow in clinical practice.

In conclusion, persistent normocalcemia in patients with NPHPT is rare. If the international guidelines were strictly applied, the prevalence of NPHPT in this population would be zero. Our study is the first that studies the natural history of patients with NPHPT in so much detail and provides data from a long follow-up period. We suggest that the definition be revisited and NPHPT be defined as having the average calcium within normal limits and not persistently normal, at least in a research setting. Subsequent hypercalcemia in these patients should be treated with caution, and any decisions for surgery should be made after persistently high levels of calcium have been confirmed. Another approach is to accept that NPHPT is a mild form of PHPT. Our recommendation for managing a patient with high PTH and normal calcium is continuous observation for the development of persistent hypercalcemic hyperparathyroidism.
Acknowledgments

We would like to thank Gemma Minett for providing support with the laboratory interpretations and Thomas Butterfield for extracting data from the hospital’s information technology storage.

Financial Support: This work was supported by a fellowship from the Medical Research Council Versus Arthritis Centre for Integrated Research into Musculoskeletal Ageing (Grant numbers MR/R502182/1, R/130188) and the Osteoporosis 2000 Support Group (to M.S.).

Author Contributions: Study design: M.S., R.E. Data collection: M.S. Data analysis and interpretations: M.S., R.M.J., and R.E. Drafting the manuscript: M.S. All the authors revised and approved the final manuscript and take responsibility for the integrity of the data analysis.

Additional Information

Correspondence and Reprint Requests: Marian Schini, MD, Clinical Research Fellow, Department of Oncology and Metabolism, The University of Sheffield, Metabolic Bone Centre, Northern General Hospital, Herries Road, S5 7AU, Sheffield, UK. E-mail: m.schini@sheffield.ac.uk

Disclosure Summary: M.S. received funding for her fellowship from the Medical Research Council Centre of Excellence for Musculoskeletal Ageing and from Osteoporosis 2000 support group, and grant funding from Roche diagnostics. R.M.J., E.O., and N.E.A.P. have nothing to disclose. J.S.W. has received speaker honoraria from Eli Lilly and Sandoz; grant funding from Alexion and ImmunoDiagnostics System; donation of drug from Eli Lilly; Prostrakan (Kyowa Kirin) and Consilient for clinical studies; donation of assay kits from Biomedica; and consulting fees from Shire, Mereo Biopharma, Kyowa Kirin, UCB Pharma, and PharmaCosmos. R.E. receives consultancy funding from IDS, Roche Diagnostics, GSK Nutrition, FNIH, Mereo, Lilly, Sandoz, Nittobo, Abbvie, Samsung, and Haoma Medica; and grant funding from Nittobo, IDS, Roche, Amsgen, and Alexion.

References

1. Eastell R, Arnold A, Brandi ML, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009;94(2):340–350.

2. Eastell R, Brandi ML, Costa AG, D’Amour P, Shoback DM, Thakker RV. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3570–3579.

3. Yacobi-Bach M, Serebro M, Greenman Y, Tordjman K, Stern N. Letter to the editor: Thiazides are not inducers of PTH secretion: a comment on normocalcemic hyperparathyroidism. J Clin Endocrinol Metab. 2015;100(2):L27–L28.

4. Silverberg SJ, Clarke BL, Peacock M, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3580–3594.

5. Pawlowska M, Cusano NE. An overview of normocalcemic primary hyperparathyroidism. Curr Open Endocrinol Diabetes Obes. 2015;22(6):413–421.

6. Norman J, Goodman A, Politz D. Calcium, parathyroid hormone, and vitamin D in patients with primary hyperparathyroidism: normograms developed from 10 000 cases. Endocrin Pract. 2011;17(3):384–394.

7. Barth JH, Fiddy JB, Payne RB. Adjustment of serum total calcium for albumin concentration: effects of non-linearity and of regression differences between laboratories. Ann Clin Biochem. 1996;33(Pt 1):35–38.

8. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf. Accessed February 27, 2020.

9. Rousseau PJ, van Zomeren BC. Unmasking multivariate outliers and leverage points. Journal of the American Statistical Association. 1990;85(416):633–639.

10. Van Aelst S, Rousseau P. Minimum volume ellipsoid. Wiley Interdisciplinary Reviews: Computational Statistics. 2009;1(1):71–82.

11. Palermo A, Jacques R, Gossiel F, et al. Normocalcaemic hyperparathyroidism: prevalence and effect on bone status in older women. The OPUS study. Clin Endocrinol (Oxf). 2015;82(6):816–823.

12. Bland JM, Altman DG. Measurement error. BMJ. 1996;313(7059):744.

13. Aspray TJ, Bowring C, Fraser W, et al.; National Osteoporosis Society. National osteoporosis society vitamin D guideline summary. Age Ageing. 2014;43(5):392–395.

14. Wörcester EM, Cole FL. New insights into the pathogenesis of idiopathic hypercalcemia. Semin Nephrol. 2008;28(2):120–132.

15. Marques TF, Vasconcelos R, Diniz E, Régo D, Griz I, Bandeira F. Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat? Arq Bras Endocrinol Metabol. 2011;55(5):314–317.

16. Šiprová H, Fryšák Z, Souček M. Primary hyperparathyroidism, with a focus on management of the normocalcemic form: to treat or not to treat? Endocr Pract. 2016;22(3):294–301.

17. Berger C, Almohareb O, Langsetmo L, et al.; CaMos Research Group. Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers. Clin Endocrinol (Oxf). 2015;82(3):359–368.

18. Cusano NE, Maalouf NM, Wang PY, et al. Normocalcemic hyperparathyroidism and hyperparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab. 2013;98(7):2734–2741.

19. Garcia-Martín A, Reyes-Garcia R, Muñoz-Torres M. Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women. Endocrine. 2012;42(3):764–766.

20. Kontogeorgos G, Trimpou P, Laine CM, Oleriod G, Lindahl A, Landin-Wilhelmsen K. Normocalcemic, vitamin D-sufficient hyperparathyroidism - high prevalence and low morbidity in the general population: A long-term follow-up study, the WHO MONICA project, Gothenburg, Sweden. Clin Endocrinol (Oxf). 2015;83(2):277–284.

21. Lundgren E, Rastad J, Thrufjell E, Akerstrom G, Ljunghall S. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery. 1997;121(3):287–294.

22. Rosário PW, Caloslar MR. Normocalcemic primary hyperparathyroidism in adults without a history of nephrolithiasis or fracture: a prospective study. Horm Metab Res. 2019;51(4):243–247.

23. Vignali E, Cetani F, Chiavistelli S, et al. Normocalcemic primary hyperparathyroidism: a survey in a small village of Southern Italy. Endocr Pract. 2015;21(4):172–178.

24. Ayturk S, Gunsoy A, Bascil Tutuncu N, Ertugrul DT, Guvenner Demirag N. Changes in insulin sensitivity and glucose and bone metabolism over time in patients with asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab. 2006;91(11):4260–4263.

25. Tordjman KM, Greenman Y, Osher E, Shenkerman G, Stern N. Characterization of normocalcemic primary hyperparathyroidism. Am J Med. 2004;117(1):861–863.
26. Diri H, Unluhizarci K, Kelestimur F. Investigation of glucose intolerance in patients with normocalcemic primary hyperparathyroidism: 4-year follow-up. *Endocrine*. 2014;47(3):971–972.

27. Silverberg SJ, Bilezikian JP. “Incipient” primary hyperparathyroidism: a “forme fruste” of an old disease. *J Clin Endocrinol Metab*. 2003;88(11):5348–5352.

28. Sho S, Kuo EJ, Chen AC, Li N, Yeh MW, Livhits MJ. Biochemical and Skeletal Outcomes of Parathyroidectomy for Normocalcemic (Incipient) Primary Hyperparathyroidism. *Ann Surg Oncol*. 2019;26(2):539–546.

29. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. *J Clin Endocrinol Metab*. 2007;92(8):3001–3005.

30. Bollerslev J, Schalin-Jäntti C, Rejnmark L, et al. MANAGEMENT OF ENDOCRINE DISEASE: Unmet therapeutic, educational and scientific needs in parathyroid disorders. *Eur J Endocrinol*. 2019;181(3):P1–P19.

31. Koumakis E, Souberbielle JC, Sarfati E, et al. Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. *J Clin Endocrinol Metab*. 2013;98(8):3213–3220.

32. Lim JY, Herman MC, Bubis I, et al. Differences in single gland and multigland disease are seen in low biochemical profile primary hyperparathyroidism. *Surgery*. 2017;161(1):70–77.

33. Traini E, Bellantone R, Tempera SE, et al. Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism? *Langenbecks Arch Surg*. 2018;403(3):317–323.

34. Pandian TK, Lubitz CC, Bird SH, Kuo LE, Stephen AE. Normocalcemic hyperparathyroidism: a collaborative endocrine surgery quality improvement program analysis. *Surgery*. 2020;167(1):168–172.

35. Kiriakopoulos A, Petralias A, Linos D. Classic primary hyperparathyroidism versus normocalcemic and normohormonal variants: do they really differ? *World J Surg*. 2018;42(4):992–997.

36. Gómez-Ramírez J, Gómez-Valdazo A, Luengo P, Porro B, Osorio I, Rivas S. Comparative prospective study on the presentation of normocalcemic primary hyperparathyroidism. Is it more aggressive than the hypercalcemic form? *Am J Surg*. 2020;219(1):150–153.

37. Yu Q, Liu K, Ma D, et al. Do symptoms and serum calcium levels affect the results of surgical treatment of primary hyperparathyroidism? *Biomed Res Int*. 2019;2019:2150159.

38. Maruani G, Hertig A, Paillard M, Houllier P. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. *J Clin Endocrinol Metab*. 2003;88(10):4641–4648.

39. Díaz-Soto G, Romero E, Castrillón OI, de Luis Román D. Clinical expression of calcium sensing receptor polymorphism (A986S) in normocalcemic and asymptomatic hyperparathyroidism. *Horm Metab Res*. 2016;48(3):163–168.

40. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. *J Clin Endocrinol Metab*. 2014;99(10):3561–3569.

41. Carrivick JS, Walsh PJ, Brown JS, Wardrop CR, Hadlow CN. Brief report: does PTH increase with age, independent of 25-hydroxyvitamin D, phosphate, renal function, and ionized calcium? *The Journal of Clinical Endocrinology & Metabolism*. 2015;100(5):2131–2134.

42. Rejnmark L, Amstrup AK, Mollerup CL, Heickendorff L, Mosekilde L. Further insights into the pathogenesis of primary hyperparathyroidism: a nested case-control study. *J Clin Endocrinol Metab*. 2013;98(1):87–96.